---
title: "BOAN BIOTECH's self-developed drug Dulaglutide Injection has been approved for market launch"
description: "BOAN BIOTECH's independently developed Boyouping® (Dulaglutide Injection) has received marketing approval from the National Medical Products Administration, primarily for blood sugar control in adult "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252337903.md"
published_at: "2025-08-09T13:58:45.000Z"
---

# BOAN BIOTECH's self-developed drug Dulaglutide Injection has been approved for market launch

> BOAN BIOTECH's independently developed Boyouping® (Dulaglutide Injection) has received marketing approval from the National Medical Products Administration, primarily for blood sugar control in adult patients with type 2 diabetes. This drug is a long-acting GLP-1 receptor agonist, and its commercialization is carried out in collaboration with Shanghai Pharmaceuticals Holding

BOAN BIOTECH Hong Kong Stock Exchange announcement, the company's independently developed Boyouping® (Dulaglutide Injection) has received marketing approval from the National Medical Products Administration for blood glucose control in adult patients with type 2 diabetes. Boyouping® is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist, and its commercialization in mainland China is carried out in collaboration with Shanghai Pharmaceuticals Holding

### Related Stocks

- [06955.HK - BOAN BIOTECH](https://longbridge.com/en/quote/06955.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 恆地慶祝 50 週年 再辦兩大活動 與 3500 名長幼基層迎新歲 | 恆基地產慶祝成立 50 週年，舉辦了「馬年耆樂團年宴」和「社區同樂日」兩大活動，吸引 3500 名長者、年輕人及基層家庭參與。活動包括團年飯、非物質文化遺產展示、幸運抽獎及兒童表演，旨在營造節慶氛圍並傳遞愛心與正能量。集團與 20 多個非牟 | [Link](https://longbridge.com/en/news/276030098.md) |
| 石藥集團宣佈，羅哌卡因長效注射劑已獲准在中國開展臨牀試驗 | 石藥集團表示，羅哌卡因長效注射劑已獲得中國臨牀試驗批准 | [Link](https://longbridge.com/en/news/276051793.md) |
| 諾科達科技預計上半年將虧損 3050 萬港元 | 諾科達科技預計上半年虧損 3050 萬港元 | [Link](https://longbridge.com/en/news/275923659.md) |
| 野村將信達生物的目標價從 105.08 港元調整至 114.64 港元，並維持買入評級 | 野村將信達生物的目標價從 105.08 港元調整至 114.64 港元，維持 “買入” 評級 | [Link](https://longbridge.com/en/news/275882948.md) |
| SAL 物流公司簽署了與皇家約旦航空公司的協議 | 沙特物流服務公司 SJSC : SAL LOGISTICS - 與約旦皇家航空簽署協議 SAL LOGISTICS - 繼續提供涵蓋地面服務和空運的綜合集成解決方案 | [Link](https://longbridge.com/en/news/275995957.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.